Actavis sales and marketing update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending Ozurdex dexamethasone intravitreal implant ( SK-0503) from Actavis to treat diabetic macular edema (DME). The recommendation, which is restricted to patients with an intraocular lens who did not respond to non-corticosteroids, is in line with a February preliminary appraisal. Ozurdex is approved in adult patients with visual impairment due to DME who are pseudophakic or who are considered insufficiently responsive to or unsuitable for non-corticosteroid therapy (see BioCentury, Feb. 23). ...